JAMA Oncology
JAMA Oncology is the JAMA Network's cancer journal, publishing phase 2 trials, secondary analyses of big trials, epidemiology, health policy and drug-pricing research.
JAMA Oncology has appeared monthly since 2015 and is strong on population-based and health-services research (the Global Burden of Disease cancer updates, cost and value analyses of new drugs, disparities), single-arm phase 2 studies, and pooled or secondary analyses of major randomised trials. Hybrid access; research articles free after 12 months. Sceptical editorial tone on surrogate endpoints and accelerated approvals.
Radiation oncologist who showed MRI-guided prostate radiotherapy causes fewer side effects.
Showed that adding blood-based sequencing to tissue testing finds more targetable lung cancer mutations.
Nurse scientist who put patient-reported outcomes into cooperative group radiation trials.
Defined how prostate cancer trials are run and read, from PSA working-group criteria to circulating tumour cell biomarkers.
Nuclear medicine leader who helped bring PSMA PET and radioligand therapy to the United States.
Runs one of the world's largest phase 1 programmes and led trials that shaped head and neck cancer immunotherapy.
Mariana Chavez-MacGregor is a breast oncologist who studies how care is delivered and leads SWOG's international work.
Nuclear medicine physician who led the trials that got PSMA PET approved in the United States.